

**Oculoplastic Update: Eyelid & Lacrimal Problems 2024**

**Saturday, November 9, 2024**

*Wills Eye Auditorium*

**Conference Description:**

[Click Here to Register for the Livestream](https://attendee.gotowebinar.com/register/2134602210048612955)

This presentation will benefit comprehensive ophthalmologists and those practicing oculoplastics alike. It will touch upon novel and updated techniques in treating common plastics problems and teach proper management and triage of dangerous diseases that warrant proper diagnosis in the community.

**At the conclusion of the course, participants should be able to:**

1 Identify basic and clinical vision research that can be transformed into improved clinical care.

2 Assess the role of new technologies in the evaluation and treatment of eyelid and adnexal disease.

3 Identify clinical, scientific and ethical issues confronting the profession.

4 Describe factors that impact the effective delivery of the highest quality eye care for the public.

5 Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of eyelid and adnexal disease.

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this Live Activity for a maximum of 2.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Jackie R. Carrasco, MD | Faculty | Speakers Bureau-Horizon Therapeutics - 09/24/2024 |
| Bob Penne, MD | Peer Reviewer | Nothing to disclose - 10/09/2024 |
| Alison Watson, MD | Peer Reviewer | Nothing to disclose - 11/06/2024 |
| Michael Rabinowitz, MD | Faculty, Planner | Nothing to disclose - 10/04/2024 |
| Narmien Murdock, MD | Faculty | Nothing to disclose - 09/27/2024 |
| Nina S Boal, MD | Faculty | Nothing to disclose - 09/18/2024 |

